Oncolytics Biotech Inc ONCY:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
1.29quote price arrow up+0.02 (+1.57%)
Volume
52,320
52 week range
0.80 - 2.38
Loading...
  • Open1.28
  • Day High1.34
  • Day Low1.27
  • Prev Close1.27
  • 52 Week High2.38
  • 52 Week High Date10/21/21
  • 52 Week Low0.80
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap75.41M
  • Shares Out58.46M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta2.11
  • YTD % Change-7.19

KEY STATS

  • Open1.28
  • Day High1.34
  • Day Low1.27
  • Prev Close1.27
  • 52 Week High2.38
  • 52 Week High Date10/21/21
  • 52 Week Low0.80
  • 52 Week Low Date06/14/22
  • Market Cap75.41M
  • Shares Out58.46M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta2.11
  • YTD % Change-7.19

RATIOS/PROFITABILITY

  • EPS (TTM)-0.34
  • P/E (TTM)-3.79
  • Fwd P/E (NTM)-2.45
  • EBITDA (TTM)-18.65M
  • ROE (TTM)-63.41%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)1.70%

EVENTS

  • Earnings Date11/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Oncolytics Biotech Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Oncolytics Biotech Inc. is a biotechnology company, which is engaged in developing pelareorep, an intravenously delivered immunotherapeutic agent. The Company is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral...
Wayne Pisano
Independent Chairman of the Board
Matthew Coffey Ph.D.
President, Chief Executive Officer, Director
Kirk Look
Chief Financial Officer
Allison Hagerman
Vice President - Product Development
Address
1167 Kensington Cres Nw Suite 210
Calgary Alberta Canada T2n 1X7
Calgary, AB
T2R 0C5
Canada